(Q36577472)

15 August 2017

1 reference

title

Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies (English)

1 reference

15 August 2017

Marinos C Dalakas

1

1 reference

15 August 2017

1 April 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

219-227

1 reference

15 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/ncprheum0140

15 August 2017

0 references

cites work

Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

Differential expression of chemokines in inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

DNA microarray gene expression analysis technology and its application to neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

Severe Perturbations of the Blood T Cell Repertoire in Polymyositis, But Not Dermatomyositis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

Polymyositis, dermatomyositis and inclusion-body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Molecular immunology and genetics of inflammatory muscle diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Microvascular deposition of complement membrane attack complex in dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-β, misfolded proteins, predisposing genes, and aging

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Expression of immunoreactive major histocompatibility complex products in human skeletal muscles

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Immunobiology of muscle: advances in understanding an immunological microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Expression of IFN-gamma-inducible chemokines in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Immunocytochemical and virological characteristics of hiv-associated inflammatory myopathies: Similarities with seronegative polymyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Inclusion body myositis in HIV-1 and HTLV-1 infected patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Tapasin: an ER chaperone that controls MHC class I assembly with peptide

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0140

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0140

1 reference

PubMed ID

16932688

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

16932688